已发表的部分文献: 标题:Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.作者:Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y;杂志名称:Breast Cancer Res Treat 标题:Oct4 mediated inhibition of Lsd1 activity promotes the active and primed state of pluripotency enhancers作者:AlAbdi L. et al.;杂志名称:bioRxiv 标题:LSD1 inhibition yields functional insulin-producing cells from human embryonic stem cells.作者:He F, Li N, Huang HB, Wang JB, Yang XF, Wang HD, Huang W, Li FR;杂志名称:Stem Cell Res Ther 标题:Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.作者:Lin J, Mao H, Ji Z, Lin W, Wang T;杂志名称:J Cancer Res Ther 标题:Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells.作者:Sawesi S, Malkaram SA, Abd Elmageed ZY, Fandy TE;杂志名称:J Cell Mol Med Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。